ALTAMIRA THERAPEUTICS LTD (CYTO) Stock Price, Forecast & Analysis
USA - NASDAQ:CYTO - BMG0360L1349 - Common Stock
CYTO Key Statistics, Chart & Performance
The current stock price of CYTO is 0.3 USD. In the past month the price decreased by -31.8%. In the past year, price decreased by -89.47%.
CYTO Latest News, Press Relases and Analysis
CYTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.04 | 979.11B | ||
| JNJ | JOHNSON & JOHNSON | 19.19 | 479.67B | ||
| MRK | MERCK & CO. INC. | 10.91 | 240.16B | ||
| PFE | PFIZER INC | 7.87 | 143.19B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.19 | 96.05B | ||
| ZTS | ZOETIS INC | 18.57 | 52.18B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.56 | 22.92B | ||
| VTRS | VIATRIS INC | 4.6 | 12.49B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.12 | 10.55B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.09 | 7.89B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.40B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.07B |
Related stock screener links
About CYTO
Company Profile
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The firm has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Company Info
ALTAMIRA THERAPEUTICS LTD
Clarendon House, 2 Church Street
Hamilton ZUG BM
CEO: Thomas Meyer
Employees: 10
Phone: 410417297194
ALTAMIRA THERAPEUTICS LTD / CYTO FAQ
What does CYTO do?
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The firm has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
What is the stock price of ALTAMIRA THERAPEUTICS LTD today?
The current stock price of CYTO is 0.3 USD. The price decreased by -25.94% in the last trading session.
Does ALTAMIRA THERAPEUTICS LTD pay dividends?
CYTO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CYTO stock?
CYTO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does ALTAMIRA THERAPEUTICS LTD belong to?
ALTAMIRA THERAPEUTICS LTD (CYTO) operates in the Health Care sector and the Pharmaceuticals industry.
What is ALTAMIRA THERAPEUTICS LTD worth?
ALTAMIRA THERAPEUTICS LTD (CYTO) has a market capitalization of 1.13M USD. This makes CYTO a Nano Cap stock.
CYTO Technical Analysis
CYTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYTO. CYTO has a bad profitability rating. Also its financial health evaluation is rather negative.
CYTO Financial Highlights
Over the last trailing twelve months CYTO reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 101.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.09% | ||
| ROE | -0.11% | ||
| Debt/Equity | 0.05 |
CYTO Forecast & Estimates
7 analysts have analysed CYTO and the average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3.
For the next year, analysts expect an EPS growth of -88.67% and a revenue growth -100% for CYTO